Kim H K, Thornton A F, Greenberg H S, Page M A, Junck L, Sandler H M
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, USA.
Am J Clin Oncol. 1997 Aug;20(4):358-63. doi: 10.1097/00000421-199708000-00007.
We evaluated the potential of three-dimensional conformal therapy for re-irradiation of selected intracranial neoplasms and reviewed the retreatment of 20 patients at the University of Michigan between May 1988 and August 1991. All patients had previously undergone a full course of external beam radiotherapy (RT) to a median dose of 5,940 cGy (range 5,100-6,500 cGy), including five whole brain treatments. All recurrences were unsuitable for brachytherapy or radiosurgery. Various histologies were retreated, including 14 high-grade gliomas. Median time to re-irradiation was 38 months (range 9 months to 19 years, 6 months). RT was delivered with complex plans designed using fully integrated computed tomography/magnetic resonance imaging (CT/ MRI) tumor volume information, and regions of previous parenchymal treatment were avoided if possible. Composite (initial+retreatment) dose-volume histograms (DVH) of dose to nontarget brain allowed comparison of alternative plans to select beam orientations which minimized normal brain irradiation. Mean target dose of re-irradiation was 3,600 cGy (range 3,060-5,940 cGy). Total cumulative dose ranged from 8,060 to 11,940 cGy. Median survival was 9 months, and 1-year actuarial survival was 26%. After retreatment, 8 of 12 patients (67%) had steroid dose decrement and neurologic improvement at 4-48 months (median duration 14 months). Radiographic regression or stabilization of disease was noted in 11 of 16 patients (68%). Re-irradiation with highly conformal three-dimensional planning provides frequent clinical improvement with acceptable morbidity and should be considered in selected patients with recurrent intracranial neoplasms.
我们评估了三维适形治疗对特定颅内肿瘤再照射的潜力,并回顾了1988年5月至1991年8月期间密歇根大学20例患者的再治疗情况。所有患者先前均接受了全疗程的外照射放疗(RT),中位剂量为5940 cGy(范围5100 - 6500 cGy),其中包括5次全脑放疗。所有复发患者均不适合近距离放疗或放射外科治疗。对多种组织学类型进行了再治疗,包括14例高级别胶质瘤。再照射的中位时间为38个月(范围9个月至19年6个月)。使用完全整合的计算机断层扫描/磁共振成像(CT/MRI)肿瘤体积信息设计复杂计划进行RT,如有可能避免先前实质治疗区域。非靶区脑剂量的复合(初始+再治疗)剂量体积直方图(DVH)允许比较替代计划以选择使正常脑照射最小化的射束方向。再照射的平均靶区剂量为3600 cGy(范围3060 - 5940 cGy)。总累积剂量范围为8060至11940 cGy。中位生存期为9个月,1年精算生存率为26%。再治疗后,12例患者中有8例(67%)在4 - 48个月(中位持续时间14个月)时类固醇剂量减少且神经功能改善。16例患者中有11例(68%)出现影像学上的疾病消退或稳定。采用高度适形的三维计划进行再照射可使患者临床症状频繁改善,且发病率可接受,对于选定的复发性颅内肿瘤患者应予以考虑。